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Point by point response:  
1. Figure legends for Figure 1 and 2 are already provided - page 21 of R2 revision.  
2. Units (mg/kg/month) have now been corrected - now page 12 of R2 revision. 
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Immunoglobulin replacement therapy enhances survival and reduces infection risk in patients with 
agammaglobulinemia. We hypothesized that despite regular immunoglobulin therapy some patients 
will experience ongoing respiratory infections and develop progressive bronchiectasis with 
deteriorating lung function. 139 (70%) of 199 patients aged 1 to 80 years from nine cities in the UK 
with agammaglobulinemia currently listed on the UKPID registry were recruited to this retrospective 
case study and their clinical and laboratory features analyzed. 94% were male of whom 78% had 
BTK gene mutations. All patients were on immunoglobulin replacement therapy and 52% had 
commenced therapy by the time they were two years old. 60% were also taking prophylactic oral 
antibiotics. 56% of patients had radiological evidence of bronchiectasis, which developed between 
the ages of 7 to 45 years. Multi-variate analysis showed that three factors were significantly 
associated with bronchiectasis: reaching 18 years old (relative risk (95% CI) 14.2 (2.7 – 74.6)), history 
of pneumonia (3.9 (1.1 – 13.8)) and IVIG rather than SCIG (3.5 (1.2 – 10.1)), while starting 
immunoglobulin replacement after reaching two years old, gender and recent serum IgG 
concentration were not significantly associated. Independent of age, patients with bronchiectasis 
had significantly poorer lung function (predicted FEV1 74% (50 – 91)) than those without this 
complication (92% (84 – 101)) (p < 0.001). We conclude that despite immunoglobulin replacement 
therapy, many patients with agammaglobulinemia can develop chronic lung disease and progressive 
impairment of lung function.  
Key words: agammaglobulinemia, infection, bronchiectasis, lung function, immunoglobulin, IVIG, 
SCIG 
































































Abbreviations: BTK Bruton tyrosine kinase, BLNK B cell linker, 95% CI 95% confidence interval, CVID 
Common Variable Immunodeficiency; IG immunoglobulin; IGHM immunoglobulin heavy constant 
mu, IGLL1 immunoglobulin lambda like polypeptide 1, IQR interquartile range, IVIG intravenous 
immunoglobulin, RR relative risk, SCIG subcutaneous immunoglobulin, UKPID UK Primary Immune 
Deficiency; UK-PIN UK-Primary Immunodeficiency Network  

































































Agammaglobulinemia is a group of inherited antibody immunodeficiency diseases, which unlike 
common variable immunodeficiency (CVID), usually present in the first few years of life. Males are 
more commonly affected than females, with mutations most commonly detected in the BTK gene 
on the X-chromosome.[1] Less frequently, mutations are found in genes coding for the 
immunoglobulin heavy mu chain (IGHM), pre-B cell and B-cell receptor (IGLL1, CD79A, CD79B) and 
the scaffold protein BLNK of both males and females.[2-6] Respiratory tract and other deep-seated 
infections caused particularly by encapsulated bacteria account for much of the morbidity and 
mortality.[7,8]  
 Since the initial description of inherited agammaglobulinemia by Ogden Bruton in 1952 the 
mainstay of treatment has been immunoglobulin (IG) replacement therapy to reduce this infection 
risk.[9] With early diagnosis and IG replacement therapy, clinicians currently expect that chronic 
lung damage and bronchiectasis might be prevented, more so than in other antibody deficiencies 
presenting more insidiously and later in life i.e. CVID.[10-13] However there is evidence that 
bronchiectasis can develop in over half and progress in a third of the patients despite carefully 
monitored IG replacement.[14-18] 
 Using data from the UK-PIN national primary immunodeficiency registry, this study aimed to 
determine if IG replacement therapy protects patients with agammaglobulinemia developing 
recurrent respiratory infections and in particular bronchiectasis with concomitant impairment of 
lung function. The findings of this study should help clinicians to more accurately advise their 
patients as to the natural history of agammaglobulinemia and its potential complications, even with 
modern, well monitored IG therapy. 
  


































































Patient definition and identification 
Patients with agammaglobulinemia excluding CVID, were identified from large clinical immunology 
referral centres across the United Kingdom contributing patients to the national UK-Primary 
Immune Deficiency (UKPID) registry.[19] The UKPID registry was established in 2009 and recruits 
patients prospectively after obtaining written consent. The registry currently contains 4,460 patients 
with primary immunodeficiency diseases, 199 of whom are classified as having 
agammaglobulinemia. 
 Data from nine UK cities with patients registered with agammaglobulinemia were 
approached. The study had multi-centre ethical approval (04/MRE07/68). After requesting 
permission from Centre Principle Investigators, data were collated into a single SPSS database (IBM 
SPSS Statistics 22.0) for analysis. Clinical information included demographics, past medical history of 
acute or recurrent respiratory tract infections. UKPID registry entries are updated on an annual basis 
by CB who personally visits each of the centres to ensure that subsequent morbidity and mortality, 
as well as latest laboratory parameters are recorded. For the purposes of this survey, registry entries 
were rechecked with source data by AS, CB and centre investigators and missing data points filled. 
LRTI was defined as respiratory symptoms associated with consolidation noted on chest-x-ray. 
Bronchiectasis was diagnosed when radiological abnormalities were identified by high-resolution 
chest CT imaging. Date of diagnosis of bronchiectasis was recorded. Timing of the CT imaging 
depended on the clinician. Spirometry was not routinely recorded within the PIDUK registry 
database. For the purposes of this study, the patient’s most recent FEV1 and FVC results were 
requested from individual site investigators. There is currently no UK-wide protocol for performing 
chest CT scans or pulmonary function tests. Frequency of monitoring of lung function amongst 
































































patients in the study is not known. Therapies, including IG replacement and antibiotic prophylaxis 
were also recorded. None of the patients were documented to have spent any time off infusions. 
 
Laboratory investigations 
Laboratory data included routine hematology (hemoglobin, white blood count (WBC), absolute 
neutrophil and lymphocyte counts, and platelets) and immunology (lymphocyte subsets: absolute 
CD3, CD4, CD8, CD19, CD56) and serum immunoglobulin (Ig) concentrations) taken at diagnosis and 
on IG replacement therapy. Immunoglobulin subclasses and vaccine antibody responses were not 
available for most patients in this cohort. Lymphocyte subsets were assessed using standard 
immunofluorescent staining and flow cytometry was performed in accredited regional clinical 
immunology laboratories. Serum immunoglobulin concentrations were measured by nephelometry. 
For patients on 3 – 4 weekly intravenous immunoglobulin replacement (IVIG), trough IgG 
concentrations were checked just prior to administering the next dose; for patients on weekly 
subcutaneous immunoglobulin therapy (SCIG) levels were checked at scheduled clinic visits which 
did not necessarily occur just prior to administration of next dose.   
 
Statistical Analysis 
Analysis was conducted using the IBM SPSS Statistics 22 program. Continuous variables are quoted 
as medians and interquartile ranges. Statistical differences between groups were determined by 
Chi-square, Mann Witney or Kruskal-Wallis tests. Differences were considered statistically significant 
with a p value <0.05. Multi-variate analysis was calculated using Binominal Logistic and Cox 
Regression.   


































































One hundred and thirty nine of 199 patients (70%) classified as having agammaglobulinemia on the 
PIDUK registry were recruited from nine cities treating patients for primary immunodeficiency 
diseases within the United Kingdom. Twenty seven percent were from Manchester, 18% in London, 
12% in Newcastle, 12% in Belfast and 11% in Glasgow, with smaller numbers of patients from 
Aberdeen, Cardiff, Leeds and Nottingham. Eighty percent were white European. Only 9 (6%) were 
female. A BTK gene mutation was found in 109 (78%) of the 130 males. Two males had IGHM 
mutations. No specific genetic cause was available in the remainder. The median age of the cohort 
was 27 (range 1 - 80) years. Eighty five percent of patients' symptoms commenced by three years 
old. The median age of diagnosis was three years (93% by five years old). The median (interquartile 
range) duration of follow-up was 21 (13 - 32) years, with an overall follow-up for the total cohort of 
2,922 years. Three patients (2%) had died (Table I).   
   
Clinical and laboratory correlates with infectious complications: bacterial respiratory tract infections 
and bronchiectasis 
Seventy eight percent of patients had suffered from bacterial infections; 74% from pneumonia, 70% 
chronic sinusitis, 38% otitis and 23% conjunctivitis. Fifty six percent had bronchiectasis (Table I). 
Bronchiectasis was associated with a history of bacterial infection at any site (relative risk (95% CI) 
2.6 (1.0 - 6.3)), particularly with pneumonia (4.6 (1.8 - 11.8)) and otitis (4.2 (1.6 - 11.0)), but not 
sinusitis (1.4 (0.6 - 3.1)) or conjunctivitis (0.4 (0.2 - 1.1)) (Table I, Figure 1). Patients with 
bronchiectasis were significantly older (34 (28 - 48) years) than those without this complication (20 
(12 - 34) years) (p < 0.001) (Table I) and there was a linear increase in the proportion of patients 
































































with bronchiectasis from 18 to 60 years of age (r = 0.81, p < 0.001) (Figure 2.A). Spirometry was 
available on 73 patients (52%). Twenty of the remaining patients (14%) were too young to perform 
lung function tests. Patients with bronchiectasis (n = 46) had significantly lower FEV1 (74% (50 - 91)) 
than those without this complication (n = 24) (92% (84 - 101), p < 0.001). Fifty five percent of 
patients (25 of 46) with bronchiectasis had an FEV1 of < 70% compared with 8% (2 of 24 patients) 
without bronchiectasis, (p < 0.001). Using Cox regression multivariate analysis, the association 
between FEV1 and bronchiectasis (relative risk (95% confidence interval) 3.2 (1.8 - 5.4)) was 
independent of age. FVC was not significantly different between the two groups (89% (68 - 100) 
versus 96% (81 - 106), p = 0.2). 
 The most common bacteria isolated from respiratory secretions was Haemophilus influenzae 
(46% of total isolates), followed by Streptococcus pneumoniae (18%), Staphylococcus aureus (12%) 
and Mycoplasma pneumoniae (8%). There was no association between a particular bacterial species 
and bronchiectasis. Extra-respiratory tract infections in order of frequency were septic arthritis, 
osteomyelitis, skin infections, meningitis, septicemia and gastroenteritis. Only one patient was 
reported to have echovirus encephalitis.  
 All but one patients had low or absent B-cells and normal CD56 NK cells. Absolute T-cell 
numbers (CD3, CD4 and CD8) were within the normal range in all patients. None of the patients had 





Fifty two percent of patients had started on immunoglobulin replacement therapy by two 
years old. The current median (interquartile) immunoglobulin dose was equivalent to 538 (459 - 
705) mg/kg/month. Fifty five percent were on intravenous therapy while 45% were having the 
































































therapy administered subcutaneously. Patients on IVIG therapy were significantly older (median age 
34 years) than those on SCIG (median age 22 years), p < 0.001 (Table II). A significantly greater 
proportion of patients on IVIG than on SCIG had bronchiectasis and this association remained 
significant after adjusting for patient’s age (3.5 (1.2 – 10.1), p = 0.02).  
Patients with bronchiectasis started on IG therapy at a significantly older age than those 
without this complication (Table I, Figure 2.B). However, using Binominal Regression multi-variate 
analysis the three key variables associated with bronchiectasis were (i) reaching adulthood (>18 
years old) (14.2 (2.7 – 74.6)), (ii) history of previous pneumonia (3.9 (1.1 – 13.8)) and (iii) treatment 
with IVIG rather than SCIG (3.5 (1.2 – 10.1)). Factors that were not significant in this multi-variate 
analysis were having started IG supplementation after 2 years old, gender and recent serum IgG 
concentration. Regarding serum IgG concentration, patients with bronchiectasis were more likely to 
have been prescribed larger doses of Ig (equivalent to 598 (498 - 848) mg/kg/month) than those 
without this complication (equivalent to 511 (436 - 584), p < 0.01) and subsequently had 
significantly higher serum IgG concentrations (10.8 (8.7 - 12.9) versus 9.7 (8.5 - 11.1) g/L, p < 0.03) 
(Table I, Figure 2.C), with nearly one in five patients with bronchiectasis having an IgG concentration 
above 14.0g/L. Eighty three percent of patients in the cohort had been on immunoglobulin 
replacement therapy for more than seven years (range 0 - 43 years) prior to their diagnosis with 
bronchiectasis. There was no significant association between history of pneumonia or otitis and 
recent serum IgG concentrations above 4.0, 7.0, 10.0 or 14.0 g/L.  
Sixty percent of patients had been prescribed prophylactic antibiotics (Table I). Although the 
use of prophylactic antibiotic use did not increase significantly with age or with history of respiratory 
infections (pneumonia, otitis or bronchiectasis), their use was associated with poorer lung function 
(FEV1 75 (49 – 93) vs 90 (83 – 93), p = 0.004. These patients were also more likely to be on a higher 
































































dose of IG replacement therapy (580 (508 – 788) vs 497 (428 – 582) equivalent mg/kg/month, p = 
0.002) and have higher serum IgG concentrations (11.1 (9.3 – 12.4) vs 9.4 (8.4 – 10.4) g/L, p = 0.003). 
 Patients recruited from London were significantly older than those from other UK cities. All 
patients recruited from Newcastle upon Tyne and Belfast were white European, in contrast to 64 - 
73% of patients from London, Manchester and Glasgow (p < 0.005). There were no significant 
regional differences in age of commencement of IG therapy, dose of IG therapy, use of prophylactic 
antibiotics, serum IgG concentration or prevalence of bronchiectasis. However, London and Glasgow 
centres prescribed IVIG rather than SCIG more frequently than other centres (p < 0.005) (Table III).  

































































In contrast to the relatively large number of retrospective case studies on CVID, there are only a few 
previously published studies with over 100 agammaglobulinemia patients.[20-21] This is the largest 
study of patients with agammaglobinemia focusing on chronic lung disease and lung function.  Since 
Sweinberg et al suggested in 1991 [22] that IG replacement could prevent chronic lung damage, the 
perceived dogma of many patients and clinicians is that optimal IG therapy, good compliance and 
close monitoring can prevent lung disease.[23,24]  This retrospective case study shows that over 
half of the patients with agammaglobulinemia in our UK registry developed radiological evidence of 
bronchiectasis and poor lung function. Furthermore, these measures of lung disease occurred many 
years after starting IG replacement therapy. Three independent factors were associated with risk of 
bronchiectasis: attaining adulthood, history of previous pneumonia and treatment with IVIG rather 
than SCIG therapy. Gender, age at starting IG therapy and species of bacterial pathogen isolated 
from respiratory secretions were not significant risk factors after adjusting for age.  
  A major difference between our study and the small study of 22 patients (10 with XLA) 
performed by Sweinberg et al is that over the last 25 years, high resolution chest CT scans rather 
than chest x-rays have become the standard and a much more sensitive test for bronchiectasis. This 
is likely to at least partly explain the higher prevalence of bronchiectasis in our study.[24-25] An 
important question not addressed here is whether the observed radiological evidence of 
bronchiectasis and the poorer lung function corresponds to deterioration in patients' quality of life. 
Bryan et al in their survey of 15 patients with agammaglobinemia from the North of England 
suggested that there may well be a significant impact on patients' respiratory and overall quality of 
life.[26]  Larger studies are required to understand more fully the overall burden of disease. 
































































  There is ongoing debate as to the optimal serum IgG concentration in patients with 
agammaglobulinemia.[27-29] with some clinicians suggesting that a trough [IgG] of >4g/L is 
adequate, while others recommending a [IgG] of >10g/L to prevent the development of subclinical 
lung damage. We found no significant association between the proportion of patients with 
bronchiectasis, pneumonia, otitis or poor lung function and serum IgG cut-off concentrations of 4.0, 
7.0 or 10.0 g/L. Nineteen percent of patients, all with bronchiectasis, had an IgG concentration 
≥14.0g/L suggesting that in a subset of patients with bronchiectasis high dose IG supplementation is 
used to try and prevent further deterioration. In this regard, patients with poorer lung function were 
on more treatment, both in terms of dose of IG supplementation and use of prophylactic antibiotics. 
Whether this escalation in therapy is beneficial is not possible to determine from this study.  
  There were some regional differences, particularly in the age of the patients with the longer 
established London centers having older patients with a higher prevalence of bronchiectasis. This 
may also explain the preferential use of IVIG in London compared with most other regional centres, 
as the use of SCIG has been largely introduced into the UK over the last 20 years. Serum IgG 
concentrations were significantly lower in patients on SCIG than IVIG but, after taking the age of the 
patient into account, IVIG rather than SCIG was associated with an increased risk of bronchiectasis. 
This is a novel finding, as no previously published studies having directly compared the efficacy of 
IVIG and SCIG in preventing lung disease. Independent studies from other countries are required to 
determine if this finding can be generalized, as if confirmed it may lead to SCIG being recommended 
as the preferred route of treatment for patients with agammaglobulinemia in the future.  
  There are a number of limitations of this study. The retrospective nature is inevitable as a 
prospective study to look at the natural history of these patients is difficult. As the PIDUK registry 
has only been collecting data since 2009, deaths prior to that time would not have been recorded 
































































and therefore the study may well underestimate the severity of the clinical course. It may be that 
followed up for longer, most of these patients will eventually develop chronic lung damage and 
respiratory impairment. Alternatively, with more patient-friendly infusion modalities,[30] and more 
precise and regular monitoring, less patients would develop these pulmonary complications. The 
criteria used by clinicians in each center to order CT scans were not recorded and may have affected 
the timing of diagnosis of bronchiectasis.  Quality of life data and smoking history were not collected 
as part of our survey or the PIDUK registry. It would be useful for registries to consider collecting 
smoking history and "patient experience" as part of future routine data collection, particularly in 
view of the potential impact and cofounding effects of smoking on lung function.  Lung function 
data is currently not recorded routinely as part of the PIDUK registry and had to be requested 
directly from the center investigators. Recording of lung function data by the PIDUK and other 
registries could potentially provide an additional useful outcome measure, particularly as 
deterioration in lung function is a recognized important complication of agammaglobulinemia.   
  In conclusion, this study suggests that even with IG replacement therapy, many patients with 
agammaglobulinemia develop chronic lung disease and reduced lung function. Patients at higher 
risk are those that have reached adulthood, have a previous history of pneumonia and are on IVIG 
rather than SCIG therapy. It is important for clinicians to counsel their patients appropriately to 
avoid unrealistic expectations and promote careful long-term monitoring of lung disease particularly 
in those with higher risks.    
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Figure 1 Association between bronchiectasis and other respiratory tract infections. Orange = 
patients with no bronchiectasis, Blue = patients with bronchiectasis. * p < 0.05, ** p < 0.005 Chi-
square test.  
 
Figure 2 Factors associated with bronchiectasis. A. Current age of patients with bronchiectasis. B. 
Age at which patients with (blue) and without (orange) bronchiectasis commenced immunoglobulin 
replacement therapy. C. Recent serum IgG concentration in patients with (blue) and without 
(orange) bronchiectasis. Insert: Percentage of patients with serum IgG concentrations >4.0, >7.0, 
>10.0 and >14.0 g/L. ** p < 0.005 using Breslow or Chi-square statistics. 
  




































































Total cohort No bronchiectasis Bronchiectasis  P value 
Number  139 61 78  
Age (years) 27 (18 - 40)  20 (12 - 34) 34 (28 - 48) 0.001 
Gender 94% male 91% male 93% male 0.5 
Ethnicity 80% white European 82% white European 81% white European 1.0 
Family history 54% 59% 53% 0.6 
     
Age of onset of symptoms (years) 0 (0 - 1)  0 (0 - 1) 0 (0 - 2) 0.2 
Age at diagnosis (years) 3 (1 - 14)  3 (1 - 4) 7 (1 - 43) 0.5 
     
Bacterial infections 78% 69% 85% 0.05 
Bronchiectasis (on chest CT scan) 56% 0% 100%  
Bacterial pneumonia 74% 60% 87% 0.001 
Chronic sinusitis 70% 67% 71% 0.7 
Otitis 38% 20% 50% 0.004 
Conjunctivitis 23% 36% 18% 0.07 
Died 2% 0% 4% 0.1 
     
FEV1 (% predicted for age) 84 (56 - 94) 92 (84 - 101) 74 (50 - 91) 0.001 
FVC  (% predicted for age) 89 (78 - 103) 96 (81 - 106) 89 (68 - 100) 0.2 
     
Pre-treatment IgM (g/L) 0.0 (0.0 - 0.05) 0.1(0.0 - 0.2) 0.1 (0.0 - 0.2) 0.9 
Pre-treatment IgG (g/L) 1.0 (0.1 - 2.8) 0.9 (0.1 - 2.6) 1.1 (0.0 - 2.9) 0.9 
Pre-treatment IgA (g/L) 0.0 (0.0 - 0.0) 0.0 (0.0 - 0.1) 0.0 (0.0 - 0.2) 0.9 
CD19 (B-cells) (cells/microlitre) 0 (0 - 6) 1 (0 - 42) 0 (0 - 2) 0.2 
CD3 (T-cells) (cells/microlitre) 1,504 (1,143 - 1,980) 1,470 (1,195 - 1,945) 1,539 (1,159 - 2,049) 0.7 
Neutrophils (X 10
9
/L) 4.5 (3.3 - 6.8) 4.3 (3.0 - 6.5) 4.9 (3.5 - 7.5) 0.06 
Latest IgG (g/L) 10.1 (8.5 - 11.9) 9.7 (8.5 - 11.1) 10.8 (8.7 - 12.9) 0.02 
Latest IgG ≥ 4.0 g/L 136 (98%) 59 (96%) 76 (98%) 0.6 
































































Latest IgG ≥ 7.0 g/L 131 (94%) 55 (90%) 74 (95%) 0.5 
Latest IgG ≥10.0 g/L 75 (54%) 28 (46%) 46 (59%) 0.2 
Latest IgG ≥14.0 g/L 14 (10%) 0   (0%) 14 (18%) 0.001 
     
IG replacement IVIG 55%, SCIG 45% IVIG 58%. SCIG 42% IVIG 34%, SCIG 66% 0.008 
Dose IG (mg/kg/month) 538 (459 - 705)  510 (438 - 584) 598 (495 - 848) 0.006 
Age IG replacement commenced 
(years) 
3 (1 - 6)  1 (0 - 3) 4 (2 - 8) 0.02 
IG started when ≥2 years old 72 (52%) 20 (32%) 52 (67%) 0.002 
Prophylactic antibiotics 60% 54% 64% 0.3 
     
 
 Continuous variables are displayed as median (interquartile range) IG = immunoglobulin replacement, IVIG intravenous 
 immunoglobulin, SCIG subcutaneous immunoglobulin. Subgroups with and without bronchiectasis are compared using Chi-square test 
 for discrete variables and Mann-Whitney U test for continuous variables.   
  
































































 Table II Clinical and laboratory features of patients receiving immunoglobulin replacement intravenously and subcutaneously 
 IVIG SCIG P value 
Number (%) 73 63  
Age (years) 34 (23-47) 22 (13-32) 0.001 
Males (%) 96% 93% 0.7 
white European (%) 85% 75% 0.2 
[IgG] on IG replacement (g/L) 10.8 (9.2-12.3) 9.4 (8.0-11.2) 0.004 
Prophylactic antibiotics (%) 69% 48% 0.02 
Bacterial sepsis (%) 81% 76% 0.5 
Bronchiectasis (%) 68% 44% 0.02 
LRTI (%) 75% 74% 1.0 
Otitis (%) 42% 35% 0.5 
Sinusitis (%) 74% 67% 0.5 
Conjunctivitis (%) 19% 29% 0.3 
Immunoglobulin replacement therapy: IVIG = intravenous, SCIG = subcutaneous. LRTI = history of bacterial lower respiratory tract infections. 
Continuous variables represent medians/interquartile ranges. Mann-Whitney U test was used for continuous variables and Chi-square test for 
discrete variables to compare groups with and without complications.  
  
































































Table III Demographics, clinical features and treatment of patients with agammaglobulinemia from major UK cities 
 London Manchester  Newcastle Belfast Glasgow P value 
Number (%) 24 44 17 17 15  
Age (years) 39 (28-53) 22 (13-37) 29 (14-36) 22 (18-27) 22 (12-34) 0.002 
White European (%) 71% 64% 100% 100% 73% 0.004 
Bronchiectasis (%) 87% 46% 53% 44% 38% 0.01 
Age bronchiectasis diagnosed (years) 19 (16-29) 16 (14-35) 23 (20-23) - 18 (18-18) 0.8 
Age IG commenced (years) 4 (1-6) 3 (0-5) 7 (1-7) 2 (0-12) 2 (2-6) 0.8 
Percentage on SCIG 21% 62% 47% 60% 20% 0.004 
Dose of IG (mg/kg/month equivalent) 661 (461-1048) 511 (436-559) 612 (460-612) 584 (443-869) 518 (492-815) 0.2 
Latest [IgG] (g/L) 11.1 (9.4-13.4) 10.2 (8.4-11.8) 9.3 (8.4-10.5) 8.5 (7.4-12.4) 10.8 (10-11.4) 0.054 
Prophylactic antibiotics  59% 70% 47% 42% 50% 0.3 
 Numbers for continuous variables represent medians/interquartile ranges. Kruskal-Wallis test was used for continuous variables and Chi-
 square test for discrete variables to compare groups. IG = immunoglobulin replacement therapy.  
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